Hannah Kim

The University of British Columbia

Canada

Research Interests

Explore related searches

Professors in Canada Professors in Cancer Biology Cancer Biology professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (6)

Martin Köbel

Associate Professor

University of Calgary

CANADA

View details

C Simon Herrington

Professor

University of Edinburgh

UNITED KINGDOM

View details

Gregg Morin

Associate Professor

The University of British Columbia

CANADA

View details

Gabriel DiMattia

Western University

CANADA

View details

Stephanie Scott

Assistant Professor

Dalhousie University

CANADA

View details

Dane Cheasley

University in Western Australia

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Hannah Kim

Research Interests

Explore related searches

Contact this professor

Articles (9)

Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.

Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma.

Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression.

NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition.

Corrigendum to "Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes" [Gynecologic Oncology, Volume 157, Issue 1, April 2020, Pages 36-45].

Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma

Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.

Collaborators (6)

Martin Köbel

C Simon Herrington

Gregg Morin

Gabriel DiMattia

Stephanie Scott

Dane Cheasley

Make your next move.